We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OBD Oxford Biodynamics Plc

0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biodynamics Plc LSE:OBD London Ordinary Share GB00BD5H8572 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.85 8.70 9.00 - 124,627 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.34M -10.83M -0.0535 -1.65 17.9M
Oxford Biodynamics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBD. The last closing price for Oxford Biodynamics was 8.85p. Over the last year, Oxford Biodynamics shares have traded in a share price range of 8.50p to 51.00p.

Oxford Biodynamics currently has 202,303,415 shares in issue. The market capitalisation of Oxford Biodynamics is £17.90 million. Oxford Biodynamics has a price to earnings ratio (PE ratio) of -1.65.

Oxford Biodynamics Share Discussion Threads

Showing 1901 to 1924 of 1925 messages
Chat Pages: 77  76  75  74  73  72  71  70  69  68  67  66  Older
Actually it does look like he sold his placing shares.How strange unless just smoke and mirrors by directors in the placing which would be very disappointing
Share count rose by 35%Dr Alexandre AkoulitchevOld 6,603,082Placing shares 333,333New 6,936,415AA holding increased 5% so he got diluted
If he has the same number then he got diluted as there are more shares in issue
He’s got exactly the same number of shares he had before the placing, so it looks as if he’s just sold the shares he took up in the placing……;.or maybe changed his mind and never took up the placing shares?
It's so tempting to add here, it's below the placing price but I feel we still need uptake numbers
Did he sell or just got diluted in the fund raise
Is the director selling a bad sign. Difficult to think otherwise without further information. Does anyone know of a good reason?
And yet your name suggests you knew all along
The AIM Market is a Con Market

After years of investing on it have finally realised it

Companies just like doing Placing and Placing and hardly ever create shareholder value.

Tower Resources (TRP) is the Stock to be in
The Stockholm 3 test is considerably cheaper. From the research information I could find it would appear to reduce the need for biopsy by 30% compared to the PSE test reducing biopsies by about 75%

On a cost/benefit analysis approach the two tests show similar benefit.

However, as the customer with a high PSA I would choose the more expensive PSE test if I could afford it.

I agree that there is room in the market for a number of tests.

Being somewhat familiar with prostate issues I've just made a small investment here.The Stockholm 3 test is cheaper but there is room for a number of tests in the market.I bought 10,000 so really just a toe dip.I still like a small gamble.
And in the US it is in the insurers commercial interest for a man to have a blood test before proceeding with a biopsy.

If the blood test rules out the biopsy they save $2,000 per person. For 1 in 4 men they will go on to have the biopsy but there is a net overall financial saving to the insurer to promote the test?

As an illustration; four men have a positive PSA test. They all have a blood test costing $4,000 in total and one has to go on to have a biopsy costing $2,000. So a total cost of $6,000.

Compared to all four going straight to biopsy costing $8,000. A 25% cost saving of at least $2,000 by having the PSE test first.I say at least because at least one of the four will have complications from the biopsy potentially costing many thousands of dollars to treat.

Have I got the commercials right and therefore the insurers would want to promote the PSE test? And presumably a large proportion of the 1m going for biopsy each year will have insurer coverage of some form.

I have just bought in here. I think the Prostate test in particular has great potential.

A biopsy in the US typically costs $2,000 and 75% of them turn out to show no cancer. In addition 40% of biopsies lead to complications. An infection typically costs $19,000 to treat. You can easily see why someone would choose to pay $1,000 for a PSE test that is 94% accurate before going ahead with a biopsy.

With 1m biopsies a year in the US it's a big market. Then there is the rest of the world to test.

The company is targeting 1,000 tests per month which works out at 1% of those people about to have a biopsy in the US alone. They have insurer coverage and now have the funds to grow awareness and build from the 180 tests they performed in January 2024 being the first month.

I know I would want to have a simple blood test if I had a positive PSA before proceeding with an invasive, uncomfortable, risky and possibly not necessary biopsy and I believe the UK lab can provide that from April 2024.

In addition over the next 12 months thay have the two new tests ready to partner/licence as well as building revenue from the CiRT test.

I accept they may well need to raise again in 12 months but I would hope they will have gained considerable momentum and have one or two positive bits of news by then. And be raising at a higher price than today.

As usual time will tell but for me it is a fair risk/reward to have a small punt at this stage.

Well at least it's done now, they are now well funded, maybe not to full production but one partnership deal will really see this fly
Not when you consider they have not signed any contracts or shown any increase in revenue and are massively loss making an swill be for some years yet. The money raised yesterday won't last them a year and they will be back for more then which will likely be at even lower price.

Said it would be sub 10p and here it is.

Although only sold 180 PSE tests to 9/2, the figure at 17/1 (see their results) was 144, so they’ve sold 36 tests in 23 days, which is 570 annualised and that’s before getting this latest slug of cash to increase sales force etc.
To be able to buy OBD at 9p, which is 2p cheaper than the last placing when there had been no mention of any PSE test looks a bit of a bargain to me.

At 17/01/24 144 PSE tests had been performed

At 09/02/24 180 PSE tests had been performed

36 tests in 3 weeks, they’re aiming for 1000 per month. That’s a long road but at least it has started.

We’ll at least we should have a floor in the share price

1.25m is just the primary bid raise they are raising another 9m from existing and new investors
Good that HL on the ball….i wonder what you could have done though if you weren’t an existing shareholder?
The Primary Bid blurb does state the fund raise is for both existing and new investor…..i do wonder how possible this would be for new investors in view of the tight timescale?

JAF111 not sure about II but on HL if you go into the account in which you hold the shares there is a corporate action symbol against OBD which isn't there for the other holdings and you click on that. Not sure if it might be similar. I also had a message about it in my HL messages.
This will good news funding concerns out the wayOnwards and upwards
And the chart says it all.

Listed in ~2007 & the share price has fallen by miles....& now raising money at a low.
A successful company would raise money at higher prices.

Looks like my post on 25th Feb. was correct.


And let me copy & paste a snippet from poster Pompei
"I'm surprised it's struggling cash wise. If this is the game changer it's presented as it should be a no brainer ?"

....the reality imo is that it does not have a prostate cancer test, despite it appearring to claim that it does.
(Imo it has a DNA related test, which indicates the likelihood of getting prostate cancer, that is very different.

As a result the sale of 'tests' has not rocketted skywards which is what would happen for an accurate blood test for prostate cancer.

Chat Pages: 77  76  75  74  73  72  71  70  69  68  67  66  Older

Your Recent History

Delayed Upgrade Clock